Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma: A Three-Dimensional Visualization Perspective
Yong Tan1, Ping-Ping Li2, Hui Liu1
1Department of Hepatobiliary Surgery, Yuebei People's Hospital, Shaoguan, Guangdong, 512026, People's Republic of China.
Journal of Hepatocellular Carcinoma
|May 5, 2025
Summary
Hepatic arterial infusion chemotherapy (HAIC) for liver cancer (HCC) needs better precision. Calculating drug doses by target tumor volume, not just body surface area, can improve individualized treatment for HCC patients.
Area of Science:
- Hepatocellular Carcinoma Research
- Precision Oncology
- Medical Imaging and Dosimetry
Background:
- Hepatic arterial infusion chemotherapy (HAIC) is a key treatment for hepatocellular carcinoma (HCC) in Asia.
- Current HAIC dosing relies on body surface area, leading to inaccurate drug delivery.
- This imprecision can cause underdosing in large tumors/liver volumes and overdosing in small ones.
Purpose of the Study:
- To propose a more precise method for calculating HAIC drug dosages.
- To enhance individualized and standardized therapy for HCC patients.
- To align HAIC with precision oncology principles.
Main Methods:
- Evaluating the limitations of current body surface area-based HAIC dosing.
- Exploring the concept of target volume-based dosing for HAIC.
- Analyzing the potential for improved drug delivery accuracy.
Main Results:
- Body surface area-based dosing is inadequate for precise HAIC drug delivery in HCC.
- Target volume-based dosing offers a potential solution for accurate drug delivery.
- Individualized dosing can optimize therapeutic outcomes for HCC.
Conclusions:
- Rethinking HAIC dosing strategies is crucial for effective HCC treatment.
- Implementing target volume-based dosing can advance precision oncology for HCC.
- A shift towards individualized dosing will improve the standardization and efficacy of HAIC.
